The Science
At the core of Prosemble’s technology is a patented protein-based nanoparticle system, distinct from existing drug carriers like albumin or ferritin.
These nanoparticles remain monomeric until they polymerise in response to ATP and subsequently depolymerise under ATP hydrolysis or low pH conditions, ensuring targeted drug release. The atomic structure has been determined through cryo-electron microscopy, enabling precise engineering for disease-specific targeting. This system successfully integrates various therapeutic payloads, including Doxorubicin and small proteins, offering a scalable and adaptable solution for oncology treatments.
Key Features
Protein-Based Nanoparticle System
Designed for controlled drug delivery, polymerising in response to ATP and breaking down under tumour-specific conditions.
ATP-Responsive & pH-Triggered Release
Ensures precise drug activation within the tumour microenvironment, minimising systemic toxicity.
Versatile Cargo Loading
Capable of encapsulating a wide range of therapeutics, from chemotherapy agents like Doxorubicin to small proteins.
Atomic-Level Precision
Cryo-EM structure determination enables fine-tuned engineering for targeted therapy, maximising treatment efficiency.
Cost-Effective Alternative to ADCs
Unlike antibody-drug conjugates (ADCs), our technology offers a significantly lower manufacturing cost, making it more accessible and scalable.
AI & Data Science
Prosemble’s AI-driven drug formulation platform enhances precision medicine by predicting optimal nanoparticle formulations, drug interactions, and release profiles.
Our proprietary AI model analyses vast datasets to refine encapsulation methods, ensuring optimal drug stability and efficacy. By addressing multi-drug interactions and optimising dosing strategies, our technology
accelerates development, reduces trial-and-error, and streamlines regulatory approvals. This data-driven innovation helps pharmaceutical partners bring safer, more effective therapies to market faster,
transforming cancer care through advanced AI integration. Combining proprietary AI models with cutting-edge neural networks, we bridge chemistry and medicine through a holistic, multi-endpoint approach.
Trained on curated datasets, our models uncover novel encapsulation methods and synergistic drug combinations that enhance safety and efficacy. By leveraging structural biology, cheminformatics, and high-quality data, we deliver robust, reliable results, giving partners a distinct edge in therapeutic development.
Through Our Science We Are Transforming Cancer Treatment for Chemotherapy Patients
